Dr. Lovly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 The Vanderbilt Clinic
Nashville, TN 37232Phone+1 615-322-5000
Education & Training
- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
- Vanderbilt University Medical CenterResidency, Internal Medicine, 2006 - 2008
- Washington University in St. Louis School of MedicineClass of 2006
- Johns Hopkins UniversityBA, Chemistry, 1993 - 1997
Certifications & Licensure
- TX State Medical License 2023 - 2026
- TN State Medical License 2012 - 2025
- AL State Medical License 2020 - 2020
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Women Leaders in Oncology Recognition for exemplifying leadership in oncology and serving as mentors and advocate Women Leaders in Oncology, 2022
- Asclepios Award honoring research pioneers in the fight to end lung cancer GO2 Foundation for Lung Cancer Research, 2022
- ECOG-ACRIN Clinical Trials Network Young Investigator Award 2021
- Join now to see all
Clinical Trials
- ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors Start of enrollment: 2018 Apr 23
Publications & Presentations
PubMed
- New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.Christine M Lovly
Journal of Clinical Oncology. 2024-10-10 - Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics.Claiborne W Tydings, Bhuminder Singh, Adam W Smith, Kaitlyn V Ledwitch, Benjamin P Brown
Protein Science. 2024-10-01 - 2 citationsEfficacy and Safety of Taletrectinib in Chinese Patients WithNon-Small Cell Lung Cancer: The Phase II TRUST-I Study.Wei Li, Anwen Xiong, Nong Yang, Huijie Fan, Qitao Yu
Journal of Clinical Oncology. 2024-08-01
Journal Articles
- Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancerChristine M Lovly, Kelli L Boyd, Paula I Gonzalez-Ericsson, Cindy L Lowe, Hunter M Brown, Robert D Hoffman, Brent C Sterling, Meghan E Kapp, Douglas B Johnson, Prasad ..., medRxiv, 5/1/2020
- Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumorsHornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM., Mod Pathol, 5/28/2015
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral C...Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM., Cancer Immunol Res, 5/3/2015
- Join now to see all
Press Mentions
- Genomic Analysis of SCLC Tumors Reveals Subtypes, Offers Cues Toward Personalized TreatmentsMay 11th, 2023
- Lovly Receives Asclepios Award from GO2 for Lung CancerDecember 8th, 2022
- GO2 Foundation for Lung Cancer Expands Scientific Leadership Board in Effort to Double Five-Year Survival Rate by 2025August 5th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: